Given that we were just discussing the need for research to develop noradrenergic drug therapies that work on the noradrenaline receptors...I am happy to share the news that Santhera in Europe has entered into agreement with Biovail to exclusively produce and market Fipamezole (JP-1730) as treatment for PD - it is in clinical trial and targets controlling dyskinesia and prolongs benefit of levodopa. We need this!!! Stay tuned....Phase III trials in US slated for 2011.


http://www.medicalnewstoday.com/articles/161643.php